Global Lung Surfactants Market growing at a CAGR of 4.0% from 2023 to 2030
Category : Healthcare | Published Date : Sep 2023 | Type : Press Release
Key Market Overview
Consegic Business Intelligence analyzes that the lung surfactants market is predicted to grow at a compound annual growth rate of 4.0% from 2023 to 2030 and is expected to reach USD 245.53 million in 2030 which was valued at USD 180.44 million in 2022.
The report highlights the increasing adoption of lung surfactants for the treatment of respiratory distress syndrome (RDS) in premature babies, which is proliferating global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the lung surfactants market.
Global Lung Surfactants Market By Overview
The lung surfactants market is bifurcated into drug type, indication, distribution channel, and end user. Based on drug type the market is segmented into lucinactant, colfosceril palmitate, beractant, calefacient, protectant alfa. In 2022, the lucinactant segment dominate in the overall lung surfactants market. The indication segment is categorized into respiratory distress syndrome (RDS), respiratory infections, and others. In 2022, the respiratory distress syndrome (RDS) segment accounted for the highest market share in the lung surfactants market. The distribution channel segment is categorized into hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2022, the hospital pharmacy segment accounted for the highest market share in the lung surfactants market. The end user segment is categorized into hospitals, specialty clinics, and others. In 2022, the hospital segment accounted for the highest market share in the lung surfactants market.
Get Free SampleMarket Dynamics
Driver:
- The increasing prevalence of respiratory distress syndrome is propelling the market growth.
- Rising government initiatives and support are accelerating market growth.
Restraints:
- The higher cost of lung surfactants is posing a major bottleneck for market growth.
Market Segmentation:
| Report Attributes | Report Details |
| By Drug Type | Lucinactant, Colfosceril Palmitate, Beractant, Calefacient, and Protectant Alfa |
| By Indication | Respiratory Distress Syndrome (RDS), Respiratory Infections, and Others |
| By Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
As per the study, the market is dominated by certain major companies such as ONY Biotech Inc, Lyomark Pharma GmbH, Windtree Therapeutics, Inc, and Aviva Systems Biology Corporation, which have a strong market position in current market circumstances. These companies are continuously leveraging innovative technologies to develop more effective and innovative products, ensure superior functioning, and others. Furthermore, the lung surfactants market is expected to witness substantial growth in the coming years due to the growing investment in advanced technology globally.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.
- ONY Biotech Inc
- Lyomark Pharma GmbH
- AbbVie Inc.
- Windtree Therapeutics, Inc
- Aviva Systems Biology Corporation
- Boehringer Ingelheim International GmbH.
- Nanjing Norris Pharm Technology
- CHIESI Farmaceutici S.p.A.
